Compare Charles River Laboratories Intl. Inc (CRL) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Prudential PLC — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: Prudential PLC is far larger — about 2× Charles River Laboratories Intl. Inc's market cap, and Prudential PLC pays a 2.33% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Prudential PLC for 119 Days on average.
| CRL | PUK | |
|---|---|---|
Market Cap | $14.23B | $28.84B |
Volume | 1,176,885 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $310.77 | $33.61 |
52-Week Low | $149.93 | $23.54 |
Typical Hold Time | 33 Days | 119 Days |
Enterprise Value | $17.06B | $28.38B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Prudential Public Limited Company (PUK) trades at $23.92, up 1.61% over 24 hours, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $27.39B in 2025 and a net income of $3.98B, with improving profitability margins and a low P/E of 8.4. Recent news highlights strategic shifts, including the sale of its Alexforbes stake and a focus on core markets.
The outlook is mixed: solid fundamentals and analyst 'Moderate Buy' consensus support upside, but technical weakness and earnings misses pose near-term risks. Key opportunities include capital return initiatives and cost savings; risks involve execution of strategic overhaul and emerging market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
